Lymphoma Obinutuzumab plus Lenalidomide ( GALEN ) for the treatment of relapse / refractory aggressive lymphoma : a phase II LYSA study

Roch Houot ● Guillaume Cartron ● Fontanet Bijou ● Sophie de Guibert ● Gilles A. Salles 4 ● Christophe Fruchart ● Krimo Bouabdallah ● Marie Maerevoet ● Pierre Feugier ● Steven Le Gouill ● Hervé Tilly ● Rene-Olivier Casasnovas ● Cécile Moluçon-Chabrot ● Eric Van Den Neste ● Pierre Zachee ● Marc Andre ● Christophe Bonnet ● Corinne Haioun ● Achiel Van Hoof ● Koen Van Eygen ● Lysiane Molina ● Emmanuelle Nicolas-Virelizier ● Philippe Ruminy ● Franck Morschhauser

[1]  E. Campo,et al.  Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma , 2017, British journal of haematology.

[2]  J. Leonard,et al.  A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance) , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Cerhan,et al.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. , 2017, Blood.

[4]  J. Burke,et al.  Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Staudt,et al.  A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2017, Clinical Cancer Research.

[6]  P. Zinzani,et al.  Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab , 2016, Haematologica.

[7]  J. Radford,et al.  Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. , 2016, The Lancet. Oncology.

[8]  Sonali M. Smith,et al.  Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. , 2015, The New England journal of medicine.

[9]  M. Czuczman,et al.  Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Michael L. Wang,et al.  Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial , 2013, Leukemia.

[11]  G. Salles,et al.  Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Pileri,et al.  Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. , 2011, Clinical lymphoma, myeloma & leukemia.

[13]  J. Vose,et al.  An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.